← boardnext 2027-07-30next 2027-08-30
ONCY
Oncolytics Biotechdistress 7/10 · high distress / dilution risk$0.82-1%today-42% from 52w high
Lead: Ras-mutated Metastatic Colorectal Cancer · est. market ~$12B (approx, global)
Revenue
pre-revenue
Liquidity
$5M
Runway
0.3 yrs
Shares 1y
+3%
Price & events
-35.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.8%
1D
-6.5%
1W
-12.4%
1M
-24.5%
3M
-33.6%
6M
-30.8%
1Y
-19.3%
2Y
-67.2%
5Y
-64.8%
All
Overview
- Market Cap
- $98.24M
- Volume
- 142.13K
- 52 Week Range
- $0.78 – $1.42
- Total Shares
- 119.35M
- Float Shares
- 116.90M
- Short %
- 5.65%
- % Held by Insiders
- 2.19%
- % Held by Institutions
- 3.31%
- RVOL
- 0.10x
- Beta
- 1.09
Pipeline stages · 2 programs
Pelareorep, Atezolizumab, Gemcitabine and nab-paclitaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Bevacizumab, FOLFIRI, Pelareorep
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-07-30 Estimated 50% readout ~2027-09-13 | Phase 1/2 | Pelareorep, Atezolizumab, Gemcitabine and nab-paclitaxelfast track | Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic, Unresectable Pancreatic Carcinoma | — | active not recruiting |
| 2027-08-30 Estimated 50% readout ~2027-10-14 | Phase 2 | Bevacizumab, FOLFIRI, Pelareorep | Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer | — | recruiting |
Catalyst news & presentations · 5
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- ASCO 2026conferencedata presentationsecondarypelareorep · Translational data from GOBLET and AWARE-1 studies.SEC 8-K
- 2026-04-27fda agreementpelareorep · FDA aligns on plans for a controlled randomized pivotal study in squamous cell carcinoma of the anal canal.SEC 8-K
- March 2, 2026trial initiationsecondarypelareorep · Launch of randomized study REO 033 in second-line RAS-mutant MSS mCRC patients.SEC 8-K
- January 12, 2026readoutpelareorep · Updated GOBLET Cohort 4 data for pelareorep plus atezolizumab.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $5 (+511% upside) · 6 analysts
- 2026-05-26HC Wainwright & Co.Buy
- 2025-11-17HC Wainwright & Co.Buy
- 2025-08-13Lake StreetBuy
- 2025-05-21HC Wainwright & Co.Buy
- 2025-05-16Jones TradingBuy → Hold
- 2025-03-10Maxim GroupBuy
Competitors — Ras-mutated Metastatic Colorectal Cancer
- CRDFCardiff Oncology, Inc.$59M · D3
Recent news
- 2026-07-21ONCY Q3 2025 Earnings: Wider-Than-Expected Loss on Elevated R&D Investment - Quarterly Profit Report - dars.gov.et
- 2026-07-21Oncolytics (ONCY) Receives FDA Fast Track Designation for Pelare - GuruFocus
- 2026-07-20Stocks in play: Oncolytics Biotech Inc - Barchart.com
- 2026-07-20Stocks in play: Oncolytics Biotech Inc - The Globe and Mail
- 2026-07-20Oncolytics (ONCY) Receives FDA Fast Track Designation for Pelare - GuruFocus
- 2026-07-20Oncolytics wins US FDA Fast Track for pelareorep in anal cancer - AllSci
- 2026-07-20Oncolytics receives FDA Fast Track for pelareorep plus checkpoint inhibitor in second-line+ anal cancer - TradingView
- 2026-07-20FDA grants fast track status to Oncolytics’ anal cancer therapy By Investing.com - Investing.com Canada
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.